reports
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatmen...
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type SHENZHEN, CHINA, Jan. 08, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”) with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” o...
China Medical System: First Prescriptions for Innovative Drug Lumeblue...
China Medical System: First Prescriptions for Innovative Drug Lumeblue® Issued in China SHENZHEN, CHINA, Dec. 08, 2024 (GLOBE NEWSWIRE) -- On 6 December, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicated for ...
China Medical System Gained Exclusive Commercialization Right of Class...
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia SHENZHEN, CHINA, Dec. 02, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmac...
China Medical System: New Drug Application for Vitiligo Indication of ...
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China SHENZHEN, CHINA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). This is another substantial milestone for ruxolitinib cr...
China Medical System Holdings Ltd: 1 director
A director at China Medical System Holdings Ltd bought 500,000 shares at 8.110HKD and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
China Medical System （00867） Released its 2024 Interim Results: Steady...
China Medical System （00867） Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 CMS enters the "New Product Era" driven by exclusive and innovative products, with exclusive and innovative drugs revenue accounts for over 56%. SHENZHEN, CHINA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- On August 15, 2024, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, ...
China Medical System: NDA for Additional Rheumatoid Arthritis Indicati...
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China SHENZHEN, CHINA, Aug. 05, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the “Product”) has been approved by the National Medical Products Administration of China (NMPA). The Product is a small-volume methotrexate injection with various strengths for the treat...
China Medical System （867.HK） Reincluded in S&P Global Sustainability ...
China Medical System （867.HK） Reincluded in S&P Global Sustainability Yearbook （China Edition） and Maintained MSCI ESG “AA” Rating SHENZHEN, CHINA, July 16, 2024 (GLOBE NEWSWIRE) -- In July 2024, China Medical System Holdings Limited (“CMS” or the “Group”) has once again been recognized for its outstanding performance and continuous progress in sustainable development. CMS was reincluded in the 2024 Sustainability Yearbook (China Edition) issued by S&P Global, a global-leading corporate sustainability assessment institution, and maintained its "AA" rating in the updated MSCI (Morgan Stan...
China Medical System Completes Dosing of the First Subject in Phase II...
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China SHENZHEN, CHINA, June 25, 2024 (GLOBE NEWSWIRE) -- On June 25, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the “Product”) in atopic dermatitis (“AD”) in China. This is another substantial clinical development milestone for ruxolitinib cream in China, following the approval for Urge...
China Medical System: Innovative Drug Methylthioninium Chloride Enteri...
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China SHENZHEN, CHINA, June 18, 2024 (GLOBE NEWSWIRE) -- Innovative drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue®) is an oral diagnostic drug, approved by China’s NMPA for enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colore...
China Medical System: New Drug Application of Desidustat Tablets Accep...
China Medical System: New Drug Application of Desidustat Tablets Accepted in China SHENZHEN, CHINA, April 23, 2024 (GLOBE NEWSWIRE) -- Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia, including both dialysis and non-dialysis patients. China Phase III trial of the Product has demonstrated positive results. The primary endpoint has indicated that Desidustat...
CMS and Incyte Announce Collaboration and License Agreement for Povorc...
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to announce that on 31 March 2024, that the Group,...
China Medical System （867.HK）2023 Annual Results: Despite of the Tempo...
China Medical System （867.HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results. The Company recorded a turnover of RMB8,013 million, a year-on-year decrease of 12.4%; in the case that all medicines were directly sold by the Group, the turnover would be RMB 9,472 million, a year-on-year decrease of 9.8%. Profit for the year was RMB2,384 million, and no...
China Medical System (00867） Obtained Exclusive License of a First-lin...
China Medical System (00867） Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro® SHENZHEN, CHINA, Feb. 03, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 2 February 2024, the Group through its wholly-owned subsidiary entered into a Novation Agreement (the “Novation Agreement”) with Vifor Fresenius Medical Care Renal Pharma Ltd. (“VFMCRP”) and Winhealth Investment (HK) Limited (“Winhealth Investment”) for sucroferric oxyhydroxide chewable tablets Velphoro® (the “Product”). Winhealth Inves...
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufac...
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA SHENZHEN, CHINA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- On 29 December, 2023, PharmaGend Global Medical Services Pte. Ltd. (“PharmaGend”), jointly invested by China Medical System Holdings Limited (“CMS”), through its wholly-owned subsidiary CMS MEDICAL VENTURE PTE. LTD., and its non-wholly owned subsidiary Rxilient Health Pte. Ltd., with Pharmaron (Hong Kong) International Limited (“Pharmaron”) * and Healthy Goal Limited (“Legend Fund”), has entered into a lease agreement fo...
China Medical System: 4 Products Have Been Newly Included or Continued...
China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL SHENZHEN, CHINA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Innovative drugs VALTOCO (Diazepam Nasal Spray)，ILUMETRI (Tildrakizumab Injection) and rare disease drug Tetrabenazine Tablets have been newly included in China’s National Reimbursement Drug List(NRDL), XinHuoSu (Recombinant Human Brain Natriuretic Peptide for Injection) has continued to be included in NRDL.China Medical System actively responds to national policies to promote innovative products to be included in the NRDL. Up to now, 3 innov...
China Medical System: NDA for Additional RA Indication of Methotrexate...
China Medical System: NDA for Additional RA Indication of Methotrexate Injection Accepted in China SHENZHEN, CHINA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis indication of Methotrexate Injection. The Product is expected to become the first methotrexate (MTX) prefilled injection to treat RA by subcutaneous administration in China. The China bridge clinical trial of the Product’s RA indication reached...
China Medical System Gained Exclusive License of an Anti-Ischemic Stro...
China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug SHENZHEN, CHINA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Y-3, a Class 1 Innovative Drug injection, is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke. The Product has a clear mechanism of action, which is conducive to exerting brain cytoprotection effects. Meanwhile, the Product has a rapid anti-depression and anti-anxiety function, and is expected to become the first new type of brain cytoprotectant that treats both stroke and post-stroke ...
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading...
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management SHENZHEN, CHINA, July 31, 2023 (GLOBE NEWSWIRE) -- Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited (“CMS” or the “Group”), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices. MSCI is one of the most widely used, influential, and referenced rating companies in the global mar...
China Medical System Included in the First 'Sustainability Yearbook (C...
China Medical System Included in the First 'Sustainability Yearbook (China)' of S&P Global SHENZHEN, CHINA, June 29, 2023 (GLOBE NEWSWIRE) -- CMS was included into the first “Sustainability Yearbook (China)” published by S&P Global. Nearly 1600 Chinese companies were included in the selection pool, but only 88 companies, including CMS, were finally selected! Recently, S&P Global, the world's leading corporate sustainability assessment institution, has officially released the first "Sustainability Yearbook 2023 (China)". China Medical System Holdings Limited (“CMS” or the “Group”), s...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.